Minimalinvasive Implantattherapie unter Berücksichtigung der Medikation

Durch die zunehmende Akzeptanz der enossalen Implantate erwarten auch Patienten mit verschiedenen Vorerkrankungen die Durchführung einer Implantattherapie. Um mögliche perioperative internistische Komplikationen oder Risikofaktoren für das Ausbleiben einer Osseointegration auszuschließen, sollten, neben der Medikation, besonders der Konsum von Psychopharmaka und die Schwere der Krankheiten als Teil der Anamnese zur patientenspezifischen Planung abgeklärt werden. Damit das perioperative Risiko gering und das angestrebte Ergebnis langzeitstabil ist, haben sich minimalinvasive Verfahren bei internistisch eingeschränkten Patienten bewährt.

Publikationsverlauf

Artikel online veröffentlicht:
19. April 2021

• Literatur

• 1 Hadji P, Klein S, Gothe H. et al. The epidemiology of osteoporosis-Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int 2013; 110: 52-57 doi:10.3238/arztebl.2013.0052
• 2 Choukroun J, Khoury G, Khoury F. et al. Two neglected biologic risk factors in bone grafting and implantology: high low-density lipoprotein cholesterol and low serum vitamin D. J Oral Implantol 2014; 40: 110-114 doi:10.1563/AAID-JOI-D-13-00062
• 3 Aghaloo T, Pi-Anfruns J, Moshaverinia A. et al. The Effects of Systemic Diseases and Medications on Implant Osseointegration: A Systematic Review. Int J Oral Maxillofac Implants 2019; 34: s35-s49 doi:10.11607/jomi.19suppl.g3
• 4 Hadji P, Klein S, Haussler B. et al. The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther 2013; 51: 868-872 doi:10.5414/CP201931
• 5 Schiegnitz E, Al-Nawas B, Hoefert S. et al. S3-Leitlinie: Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen (2018).
• 6 Reid IR. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol 2011; 40: 1191-1196 doi:10.1007/s00256-011-1164-9
• 7 Walter C, Al-Nawas B, Wolff T. et al. Dental implants in patients treated with antiresorptive medication – a systematic literature review. Int J Implant Dent 2016; 2: 9 doi:10.1186/s40729-016-0041-7
• 8 Neugebauer J, Vizethum F, Berger C. et al. Update: Kurze, angulierte und durchmesserreduzierte Implantate – Praxisleitfaden: 11. Europäische Konsensuskonferenz (EuCC). BDIZ/EDI Konkret 2016; 20: 88-90
• 9 Stavropoulos A, Bertl K, Pietschmann P. et al. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clin Oral Implants Res 2018; 29 Suppl 18: 54-92 doi:10.1111/clr.13282
• 10 Granate-Marques A, Polis-Yanes C, Seminario-Amez M. et al. Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review. Med Oral Patol Oral Cir Bucal 2019; 24: e195-e203 doi:10.4317/medoral.22691
• 11 Gelazius R, Poskevicius L, Sakavicius D. et al. Dental Implant Placement in Patients on Bisphosphonate Therapy: a Systematic Review. J Oral Maxillofac Res 2018; 9: e2 doi:10.5037/jomr.2018.9302
• 12 Nguyen TTH, Eo MY, Cho YJ. et al. 7-mm-long dental implants: retrospective clinical outcomes in medically compromised patients. J Korean Assoc Oral Maxillofac Surg 2019; 45: 260-266 doi:10.5125/jkaoms.2019.45.5.260
• 13 Meijer HJA, Boven C, Delli K. et al. Is there an effect of crown-to-implant ratio on implant treatment outcomes? A systematic review. Clin Oral Implants Res 2018; 29 Suppl 18: 243-252 doi:10.1111/clr.13338
• 14 Abdelhafeez AAM, Shohdy KS, Ibrahim W. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis. Cancer Invest 2020; 38: 150-157 doi:10.1080/07357907.2020.1714053
• 15 Hussaini S, Chehade R, Boldt RG. et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis. Cancer Treat Rev 2021; 92: 102134 doi:10.1016/j.ctrv.2020.102134
• 16 Boquete-Castro A, Gomez-Moreno G, Calvo-Guirado JL. et al. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 2016; 27: 367-375 doi:10.1111/clr.12556
• 17 Hafner SJ. High hopes and high honours for cancer immunotherapy. Biomed J 2019; 42: 293-298 doi:10.1016/j.bj.2019.10.001
• 18 Petrovic I, Ahmed ZU, Matros E. et al. Endosseous (dental) implants in an oncologic population: a primer for treatment considerations. Quintessence Int 2019; 50: 40-48 doi:10.3290/j.qi.a41336
• 19 Donos N, Calciolari E. Dental implants in patients affected by systemic diseases. Br Dent J 2014; 217: 425-430 doi:10.1038/sj.bdj.2014.911
• 20 Brand HS. Cardiovascular responses in patients and dentists during dental treatment. Int Dent J 1999; 49: 60-66
• 21 Keats AS. The ASA classification of physical status-a recapitulation. Anesthesiology 1978; 49: 233-236
• 22 Reed GW, Cannon CP. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting. Clin Cardiol 2013; 36: 585-594 doi:10.1002/clc.22167
• 23 Jones DA, Wright P, Alizadeh MA. et al. The Use of Novel Oral Anti-Coagulantʼs (NOAC) compared to Vitamin K Antagonists (Warfarin) in patients with Left Ventricular thrombus after Acute Myocardial Infarction (AMI). Eur Heart J Cardiovasc Pharmacother 2020; DOI: 10.1093/ehjcvp/pvaa096.
• 24 van Galen KP, Engelen ET, Mauser-Bunschoten EP. et al. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2019; (04) CD011385 DOI: 10.1002/14651858.CD011385.pub3.
• 25 Kang M, Kang P. Dental Implant Therapy on a Patient With von Willebrand Disease: A Case Study. Implant Dent 2018; 27: 599-601 doi:10.1097/ID.0000000000000821
• 26 Divakar TK, Gidean Arularasan S, Baskaran M. et al. Clinical Evaluation of Placement of Implant by Flapless Technique Over Conventional Flap Technique. J Maxillofac Oral Surg 2020; 19: 74-84 doi:10.1007/s12663-019-01218-9
• 27 Poli PP, Souza FA, Ferrario S. et al. Adjunctive application of antimicrobial photodynamic therapy in the prevention of medication-related osteonecrosis of the jaw following dentoalveolar surgery: A case series. Photodiagnosis Photodyn Ther 2019; 27: 117-123 doi:10.1016/j.pdpdt.2019.05.037
• 28 Hafner S, Ehrenfeld M, Neumann AC. et al. Comparison of the bactericidal effect of cold atmospheric pressure plasma (CAPP), antimicrobial photodynamic therapy (aPDT), and polihexanide (PHX) in a novel wet surface model to mimic oral cavity application. J Craniomaxillofac Surg 2018; 46: 2197-2202 doi:10.1016/j.jcms.2018.09.006
• 29 Jiang X, Zhu Y, Liu Z. et al. Association between diabetes and dental implant complications: a systematic review and meta-analysis. Acta Odontol Scand 2021; 79: 9-18 doi:10.1080/00016357.2020.1761031
• 30 Meza Mauricio J, Miranda TS, Almeida ML. et al. An umbrella review on the effects of diabetes on implant failure and peri-implant diseases. Braz Oral Res 2019; 33: e070 doi:10.1590/1807-3107bor-2019.vol33.0070
• 31 Schwartz-Arad D, Levin L, Sigal L. Surgical success of intraoral autogenous block onlay bone grafting for alveolar ridge augmentation. Implant Dent 2005; 14: 131-138 doi:10.1097/01.id.0000165031.33190.0d
• 32 Lagunov VL, Sun J, George R. Evaluation of biologic implant success parameters in type 2 diabetic glycemic control patients versus health patients: A meta-analysis. J Investig Clin Dent 2019; 10: e12478 doi:10.1111/jicd.12478
• 33 Khan AA. Medical management of primary hyperparathyroidism. J Clin Densitom 2013; 16: 60-63 doi:10.1016/j.jocd.2012.11.010
• 34 Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants 2009; 24 Suppl: 12-27